← 전체 보충제 목록

나이아신 (HDL)

Niacin (HDL)

📑 PubMed 26편 ❤️ 심혈관

📚 관련 논문 (26편)

1.
Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials.
Metabolism: clinical and experimental 2016 PMID:27733255

1. Metabolism. 2016 Nov;65(11):1664-1678. doi: 10.1016/j.metabol.2016.08.007. Epub 2016 Aug 31. Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Sahebkar A(1), Reiner Ž(2), Simental-Mendía LE(3), Fer

2.
Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2015 PMID:25439661

2. Nutr Metab Cardiovasc Dis. 2015 Jan;25(1):9-23. doi: 10.1016/j.numecd.2014.09.003. Epub 2014 Sep 28. Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials. Verdoia M(1), Schaffer A(1), Suryapranata H(2), De Luca G(3). Author information: (1)Division of Car

3.
Efficacy of AI-Guided (GenAIS(TM)) Dietary Supplement Prescriptions versus Traditional Methods for Lowering LDL Cholesterol: A Randomized Parallel-Group Pilot Study.
Nutrients 2024 PMID:38999770

3. Nutrients. 2024 Jun 26;16(13):2023. doi: 10.3390/nu16132023. Efficacy of AI-Guided (GenAIS(TM)) Dietary Supplement Prescriptions versus Traditional Methods for Lowering LDL Cholesterol: A Randomized Parallel-Group Pilot Study. Pokushalov E(1)(2), Ponomarenko A(1), Smith J(2), Johnson M(2), Ga

4.
Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome.
PloS one 2024 PMID:38408107

4. PLoS One. 2024 Feb 26;19(2):e0296052. doi: 10.1371/journal.pone.0296052. eCollection 2024. Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome. Borja MS(1)(2), Hammerson B(1), Tang C(3), Juarez-Serrano L(2), Savinova OV(4), Harris

5.
Magnetic Resonance Imaging of Intraplaque Hemorrhage and Plaque Lipid Content With Continued Lipid-Lowering Therapy: Results of a Magnetic Resonance Imaging Substudy in AIM-HIGH.
Circulation. Cardiovascular imaging 2022 PMID:36378778

5. Circ Cardiovasc Imaging. 2022 Nov;15(11):e014229. doi: 10.1161/CIRCIMAGING.122.014229. Epub 2022 Nov 15. Magnetic Resonance Imaging of Intraplaque Hemorrhage and Plaque Lipid Content With Continued Lipid-Lowering Therapy: Results of a Magnetic Resonance Imaging Substudy in AIM-HIGH. Zhao XQ(

6.
Synergistic combinatorial antihyperlipidemic study of selected natural antioxidants; modulatory effects on lipid profile and endogenous antioxidants.
Lipids in health and disease 2016 PMID:27613388

6. Lipids Health Dis. 2016 Sep 9;15(1):151. doi: 10.1186/s12944-016-0323-3. Synergistic combinatorial antihyperlipidemic study of selected natural antioxidants; modulatory effects on lipid profile and endogenous antioxidants. Hannan PA(1), Khan JA(2), Ullah I(1), Ullah S(1). Author information:

7.
Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
Vascular health and risk management 2015 PMID:25750540

7. Vasc Health Risk Manag. 2015 Feb 24;11:165-72. doi: 10.2147/VHRM.S70907. eCollection 2015. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control. Bays HE(1), Brinton EA(2), Triscari J(3), Chen E(3), Maccub

8.
Combining niacin with statins: does it help heart health?
The Johns Hopkins medical letter health after 50 2011 PMID:22216465

8. Johns Hopkins Med Lett Health After 50. 2011 Dec;23(10):1-2. Combining niacin with statins: does it help heart health? [No authors listed] PMID: 22216465 [Indexed for MEDLINE]

9.
Hyperlipidaemia and cardiovascular disease: low HDL-cholesterol as a therapeutic target in statin-treated patients: a role for nicotinic acid (niacin)?
Current opinion in lipidology 2010 PMID:20616630

9. Curr Opin Lipidol. 2010 Apr;21(2):161-2. doi: 10.1097/MOL.0b013e32833768ea. Hyperlipidaemia and cardiovascular disease: low HDL-cholesterol as a therapeutic target in statin-treated patients: a role for nicotinic acid (niacin)? Choudhury RP. DOI: 10.1097/MOL.0b013e32833768ea PMID: 20616630 [I

10.
Simcor: a niacin/simvastatin combination.
The Medical letter on drugs and therapeutics 2008 PMID:18391898

10. Med Lett Drugs Ther. 2008 Apr 7;50(1283):25-6. Simcor: a niacin/simvastatin combination. [No authors listed] PMID: 18391898 [Indexed for MEDLINE]

11.
[Drug combinations: statins and niacin].
Arquivos brasileiros de cardiologia 2005 PMID:16400397

11. Arq Bras Cardiol. 2005 Oct;85 Suppl 5:36-41. Epub 2006 Jan 2. [Drug combinations: statins and niacin]. [Article in Portuguese] Borges JL(1). Author information: (1)Seção clínica de Cardiogeriatria, Instituto Dante Pazzanese de Cardiologia de São Paulo. Combination of statins with niacin ap

12.
Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects.
Metabolism: clinical and experimental 2006 PMID:16324916

12. Metabolism. 2006 Jan;55(1):26-34. doi: 10.1016/j.metabol.2005.06.022. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects. Hughes TA(1), Stentz F, Gettys T, Smith SR. Author informat

13.
Advances in the understanding and management of dyslipidemia: using niacin-based therapies.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2003 PMID:12901026

13. Am J Health Syst Pharm. 2003 Jul 1;60(13 Suppl 2):S15-21; quiz S25. doi: 10.1093/ajhp/60.suppl_2.S15. Advances in the understanding and management of dyslipidemia: using niacin-based therapies. Ito MK(1). Author information: (1)University of the Pacific, Thomas J. Long School of Pharmacy an

14.
Current drug treatments for lipid management.
Managed care (Langhorne, Pa.) 2002 PMID:12369341

14. Manag Care. 2002 Sep;11(9 Suppl):4-9. Current drug treatments for lipid management. Stone NJ(1). Author information: (1)Feinberg School of Medicine, Northwestern University, Chicago, USA. PMID: 12369341 [Indexed for MEDLINE]

15.
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
The New England journal of medicine 2001 PMID:11757504

15. N Engl J Med. 2001 Nov 29;345(22):1583-92. doi: 10.1056/NEJMoa011090. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. Brown BG(1), Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich

16.
Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
Clinical therapeutics 2011 PMID:21955937

28. Clin Ther. 2011 Oct;33(10):1357-64. doi: 10.1016/j.clinthera.2011.08.015. Epub 2011 Sep 28. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-c

17.
Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
Vascular health and risk management 2006 PMID:17319473

3. Vasc Health Risk Manag. 2006;2(1):87-93. doi: 10.2147/vhrm.2006.2.1.87. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study. Sharma M(1), Sharma DR, Singh V, Panwar RB, Hira HS, Mohan B, Kumar N, Shar

18.
Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
JAMA network open 2019 PMID:30977858

49. JAMA Netw Open. 2019 Apr 5;2(4):e192224. doi: 10.1001/jamanetworkopen.2019.2224. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis. D'Andrea E(1), Hey SP(1), Ramirez CL(1), Kesselheim AS(1). Author information: (1)Program on R

19.
Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
European journal of preventive cardiology 2019 PMID:30861690

15. Eur J Prev Cardiol. 2019 Mar;26(5):533-543. doi: 10.1177/2047487318816495. Epub 2018 Dec 6. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. Riaz H(1), Khan SU(2), Rahman H(3), Shah NP(1), Kaluski E(4), Lincoff AM(1),

20.
Niacin for primary and secondary prevention of cardiovascular events.
The Cochrane database of systematic reviews 2017 PMID:28616955

50. Cochrane Database Syst Rev. 2017 Jun 14;6(6):CD009744. doi: 10.1002/14651858.CD009744.pub2. Niacin for primary and secondary prevention of cardiovascular events. Schandelmaier S(1), Briel M, Saccilotto R, Olu KK, Arpagaus A, Hemkens LG, Nordmann AJ. Author information: (1)Department of Heal

21.
Role of Niacin in Current Clinical Practice: A Systematic Review.
The American journal of medicine 2017 PMID:27793642

2. Am J Med. 2017 Feb;130(2):173-187. doi: 10.1016/j.amjmed.2016.07.038. Epub 2016 Oct 26. Role of Niacin in Current Clinical Practice: A Systematic Review. Garg A(1), Sharma A(2), Krishnamoorthy P(3), Garg J(4), Virmani D(5), Sharma T(6), Stefanini G(7), Kostis JB(8), Mukherjee D(9), Sikorskaya

22.
Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of relevant preclinical studies and clinical trials.
European journal of pharmacology 2015 PMID:25989133

26. Eur J Pharmacol. 2015 Sep 15;763(Pt A):48-63. doi: 10.1016/j.ejphar.2015.03.089. Epub 2015 May 16. Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of releva

23.
Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
Vascular medicine (London, England) 2014 PMID:24391126

48. Vasc Med. 2014 Feb;19(1):54-66. doi: 10.1177/1358863X13515766. Epub 2014 Jan 3. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials. Sahebkar A(1). Author information: (1)Biotechnology Research Center, Mashhad University of Medical

24.
Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis.
International urology and nephrology 2014 PMID:24114284

38. Int Urol Nephrol. 2014 Feb;46(2):433-42. doi: 10.1007/s11255-013-0559-z. Epub 2013 Oct 11. Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis. He YM(1), Feng L, Huo DM, Yang ZH, Liao YH. Author information: (1)Renal Division, Depart

25.
Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values.
Cardiovascular drugs and therapy 2013 PMID:23893306

33. Cardiovasc Drugs Ther. 2013 Oct;27(5):465-79. doi: 10.1007/s10557-013-6477-6. Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Rosenson RS(1), Underberg JA. Author information: (1)Icahn School of Medicine at Mount Sinai, New York, NY, 10029,

26.
The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
Journal of the American College of Cardiology 2013 PMID:23265337

25. J Am Coll Cardiol. 2013 Jan 29;61(4):440-446. doi: 10.1016/j.jacc.2012.10.030. Epub 2012 Dec 19. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. Lavigne PM(1), Karas RH(2). Author information: (1)Molecular Cardiology Research Instit

⚠️ 면책 고지

이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.